Clinical Trial Update: Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder [Phase 3]

View source ↗

Summary

Long-term safety study results for CAM2038 (buprenorphine) in adults with opioid use disorder have been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• CAM2038 (buprenorphine)

Snippet

Sponsor: Braeburn Pharmaceuticals | Conditions: Opioid Use Disorder | Phase 3 | Status: COMPLETED | Results posted: 2019-08-01